What are the primary reasons for the increase in net sales and earnings in the first quarter of 2004?

The increase in net sales was primarily driven by a 6% rise in volume and a 5% favorable impact from foreign exchange fluctuations. Net earnings were boosted by higher sales and a significant pre-tax gain of $295 million from the sale of the Adult Nutritional business. Investments in R&D also increased significantly, indicating continued focus on pipeline development.

What are the key products driving growth for Bristol-Myers Squibb?

Key drivers of growth include PLAVIX (up 71%), ABILIFY (over 200% revenue increase), and ERBITUX (launched in February 2004 with $17 million in first-quarter sales). Other contributing products include PARAPLATIN and REYATAZ. The company is also experiencing strong performance in its Nutritionals segment, particularly with ENFAMIL infant formula.

What are the main legal and regulatory challenges facing the company?

The company is involved in numerous legal proceedings, including patent litigation (notably for PLAVIX), antitrust and pricing investigations, product liability lawsuits (related to PPA, SERZONE, and STADOL NS), and ERISA litigation. The company acknowledges that the aggregate impact of these legal matters could be material to its financial condition, liquidity, and results of operations.

What is the outlook for market exclusivity for Bristol-Myers Squibb's key products?

The company faces significant exclusivity losses for several key products, including GLUCOPHAGE, TAXOL, MONOPRIL, and PRAVACHOL, over the next few years. For PRAVACHOL, recent clinical study results have led to a modest decline in market share. The company anticipates these exclusivity losses will challenge its margins and is focusing on growth from new and in-line products to offset these impacts.

BRISTOL MYERS SQUIBB CO 10-Q Quarterly Report Q1 FY2004

Summary

Bristol-Myers Squibb Company (BMY) filed an amendment to its quarterly report on Form 10-Q for the period ended March 31, 2004. This amendment primarily addresses technical corrections and clarifications, including enhanced disclosures related to clinical testing of PRAVACHOL, improvements in disclosure and internal controls for income taxes, clarification on revenue recognition for consignment accounting, and expected market exclusivity periods for key products. The report indicates a strong first quarter with sales increasing 10% year-over-year to $5.2 billion, driven by volume growth and favorable foreign exchange. Net earnings rose 22% to $964 million, with basic and diluted EPS increasing to $0.50 and $0.49, respectively. The company continues to invest heavily in R&D, with expenditures up 23% to $583 million, reflecting a strategic focus on key disease areas and pipeline advancement.

Key Highlights

1Total sales for the first quarter of 2004 increased by 10% to $5.2 billion compared to the prior year, driven by a 6% increase in volume and a 5% favorable foreign exchange impact.
2Net earnings for the quarter rose 22% to $964 million, resulting in basic and diluted earnings per share of $0.50 and $0.49, respectively, up from $0.41 in the prior year.
3Research and development expenditures increased significantly by 23% to $583 million, reflecting a strategic focus on key disease areas and pipeline development.
4The company completed the divestiture of its Adult Nutritional business to Novartis in February 2004, recording a pre-tax gain of $295 million.
5Key product sales show strong performance, with PLAVIX increasing 71% and ABILIFY experiencing over 200% growth in revenue.
6The company is actively managing its legal and regulatory environment, with ongoing discussions and settlements related to various litigations and investigations, including the significant PLAVIX patent litigation.
7The amendment provides updated disclosures on market exclusivity for key products and clarifies revenue recognition practices for consignment accounting.

BRISTOL MYERS SQUIBB CO Quarterly Report (Amendment) for Q1 Ended Mar 31, 2004

Summary

Key Highlights

Frequently Asked Questions